FORM 4

obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

							` '													
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Artavan</u>	<u>us-Tsako</u>	<u>onas Spyridon</u>			1	1011	1110.	LL	[بسر						Direc	tor		10% Ov	vner	
						2. Data of Farliant Transaction (Marth (Day))										Officer (give title below)		Other (specify below)		
(Last) (First) (Middle) BIOGEN INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/02/2016									EVP, Chief Scientific Officer				r		
225 BINNEY STREET					4.15															
					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									5. Individual or Joint/Group Filing (Check Applicable _ine)					
(Street)	DCE A	1A	02142												X Forn	n filed by One	iled by One Reporting Person			
	IDGE IV	IA .	U2142 													Form filed by More than One Reporting Person				
(City)	(5	State)	(Zip)																	
		Tab	le I - No	n-Deriva	ative	Secui	ities A	cqı	uired,	Dis	posed (of,	or Ber	neficia	lly Own	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Execu ay/Year) if any		A. Deemed xecution Date, any Month/Day/Year)		Transaction Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5) Securi Benefi Owned	Securities Beneficially		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amount		(A) or (D)	Price	Transa	Transaction(s) (Instr. 3 and 4)			,iii3u. 4 <i>)</i>			
Common Stock 04/02/2				2016			M		975	975 A		\$0	3,60	3,608.9671(1)		D				
Common	Stock			04/02/2	2016				F		459		D	\$260.	\$260.54 3,149.9671 D					
		Т	able II -	Derivat (e.g., pu											/ Owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/II			Date, Transaction Code (Instr.		tion on the control of the control o	of E		6. Date Exercisable a Expiration Date Month/Day/Year)		Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)		ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					or Number															

Explanation of Responses:

Restricted

Stock Unit

Date

Exercisable

(2)

(D)

Expiration

04/02/2016

Matthew S. Gilman, Attorney in Fact for Spyros Artavanis-

of

Shares

975

0

04/05/2016

D

Title

Stock

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

04/02/2016

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{1.\} Includes\ 84.8551\ shares\ acquired\ under\ the\ Biogen\ Inc.\ employee\ stock\ purchase\ plan\ on\ 3/31/2016.$

^{2.} The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).